Conv. Plasma
Nigella Sativa

All HCQ studies
Meta analysis
study COVID-19 treatment researchHCQHCQ (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

Prophylactic effects of hydroxychloroquine on the incidence of COVID-19 in patients with rheumatic arthritis: an observational cohort study

Naderi et al., Immunopathologia Persa, doi:10.34172/ipp.2021.29
Jan 2021  
  Source   PDF   All Studies   Meta AnalysisMeta
HCQ for COVID-19
1st treatment shown to reduce risk in March 2020
*, now known with p < 0.00000000001 from 421 studies, recognized in 42 countries.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
3,800+ studies for 60+ treatments.
Prospective observational study of 215 RA patients treated with HCQ showing 9 cases, 1 hospitalization (without ICU/intubation), and no mortality.
Naderi et al., 31 Jan 2021, preprint, 7 authors.
This PaperHCQAll
Prophylactic effects of hydroxychloroquine on the incidence of COVID-19 in patients with rheumatic arthritis: an observational cohort study
Zohre Naderi, Bahar Sadeghi, Ziba Farajzadegan, Ramin Sami, Mansour Salesi, Vahid Mansouri, Babak Amra
Immunopathologia Persa, doi:10.34172/ipp.2021.29
Introduction: Rheumatoid arthritis (RA) is a systemic autoimmune disease with substantial morbidity and mortality. Anti-malarial drugs like hydroxychloroquine are indicated in several rheumatic diseases such as RA. Some reports have suggested hydroxychloroquine for prevention of COVID-19. Objectives: Whether hydroxychloroquine has prophylactic effects for COVID-19 in rheumatic patients. Patients and Methods: In this multicenter cohort-based observational study the preventive effect of hydroxychloroquine regarding the incidence and severity of COVID-19 was investigated in patients with RA who referred to rheumatology clinics of academic hospitals of Isfahan between April and July 2020 and already have been treated with hydroxychloroquine for more than three months. Around 215 patients with RA and current use of hydroxychloroquine were recruited and followed for three months. Patients' information was gathered using the medical record or by phone call. Results: The incidence of COVID-19 in this selected sample was 4.2% (n=9). Only one in nine patients needed hospitalization, without need for intubation or ICU care. Symptoms including dry cough, headache, body pain, malaise, dyspnea, fever, sore throat, chills, and chest pain, were reported to be statistically higher in COVID-19+ group. Conclusion: In contrast to the mortality rate in the general population of Isfahan, Iran (4.8% -until June 2020), no mortality has been reported in these patients. Therefore, it seems that the use of hydroxychloroquine has been able to reduce the incidence and severity of the disease after reaching steady-state levels. This finding has clinical importance, especially for rheumatic patients using immunomodulatory drugs.
Authors' contribution ZN and MS contributed to the study conception and design. Material preparation, data collection and analysis were performed by ZN, BS, ZF, MS and VM. The first draft of the manuscript was written by VM and BS and ZN, MS, RS and BA left some comments on previous versions of the manuscript. All authors read and approved the final manuscript. Conflicts of interest None to be declared. Ethical considerations The authors observed the ethical issues including plagiarism, data fabrication and publication duplication.
Balevic, Hornik, Green, Clowse, Gonzalez et al., Hydroxychloroquine in Patients with Rheumatic Disease Complicated by COVID-19: Clarifying Target Exposures and the Need for Clinical Trials, J Rheumatol, doi:10.3899/jrheum.200493
Bogdanos, Smyk, Invernizzi, Rigopoulou, Blank et al., Infectome: a platform to trace infectious triggers of autoimmunity, Autoimmun Rev, doi:10.1016/j.autrev.2012.12.005
Devaux, Rolain, Colson, Raoult, New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?, Int J Antimicrob Agents, doi:10.1016/j.ijantimicag.2020.105938
Favalli, Ingegnoli, Lucia, Cincinelli, Cimaz et al., COVID-19 infection and rheumatoid arthritis: Faraway, so close!, Autoimmun Rev, doi:10.1016/j.autrev.2020.102523
Ferro, Elefante, Puxeddu, Baldini, Bartoloni et al., COVID-19: the new challenge for rheumatologists. First update, Clin Exp Rheumatol
Garcia-Cremades, Solans, Hughes, Ernest, Wallender et al., Optimizing Hydroxychloroquine Dosing for Patients With COVID-19: An Integrative Modeling Approach for Effective Drug Repurposing, Clin Pharmacol Ther, doi:10.1002/cpt.1856
Gianfrancesco, Hyrich, Al-Adely, Carmona, Danila et al., Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry, Ann Rheum Dis, doi:10.1136/annrheumdis-2020-217871
Grange, Guilpain, Truchetet, Cracowski, Society Of, Challenges of autoimmune rheumatic disease treatment during the COVID-19 pandemic: A review, Therapie, doi:10.1016/j.therap.2020.06.013
Haladyj, Sikora, Felis-Giemza, Olesinska, Antimalarials -are they effective and safe in rheumatic diseases?, Reumatologia, doi:10.5114/reum.2018.76904
Holubar, Quintrec, Letaief, Faillie, Pers et al., Monitoring of patients with systemic lupus erythematosus during the COVID-19 outbreak, Ann Rheum Dis, doi:10.1136/annrheumdis-2020-217919
Janani, Beheshti-Nia, Ahmadi, Khazeni, Yadegarafar, Epidemiological Features and Hotspot of COVID-19 in Isfahan Province of Iran: Results of A Cohort Study, Research Square, doi:10.21203/
Lai, Shih, Ko, Tang, Hsueh, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges, Int J Antimicrob Agents, doi:10.1016/j.ijantimicag.2020.105924
Listing, Gerhold, Zink, The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment, Rheumatology, doi:10.1093/rheumatology/kes305
Loppenthin, Esbensen, Ostergaard, Ibsen, Kjellberg et al., Morbidity and mortality in patients with rheumatoid arthritis compared with an age-and sex-matched control population: A nationwide register study, J Comorb, doi:10.1177/2235042X19853484
Mathew, Ravindran, Infections and arthritis, Best Pract Res Clin Rheumatol, doi:10.1016/j.COVID19prophylaxisusinghydroxychloroquineberh.2015.04.009
Mathian, Mahevas, Rohmer, Roumier, Cohen-Aubart et al., Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine, Ann Rheum Dis, doi:10.1136/annrheumdis-2020-217566
Mehta, Mcauley, Brown, Sanchez, Tattersall et al., Correspondence COVID-19: consider cytokine storm syndromes and, Lancet
Pablos, Galindo, Carmona, Lledo, Retuerto et al., Clinical outcomes of hospitalised patients with COVID-19 and chronic inflammatory and autoimmune rheumatic diseases: a multicentric matched cohort study, Ann Rheum Dis, doi:10.1136/annrheumdis-2020-218296
Pourdowlat, Panahi, Pooransari, Ghorbani, Prophylactic Recommendation for Healthcare Workers in COVID-19
Singhal, A Review of Coronavirus Disease-2019 (COVID-19), Indian J Pediatr, doi:10.1007/s12098-020-03263-6
Smolen, Aletaha, Koeller, Weisman, Emery, New therapies for treatment of rheumatoid arthritis, Lancet, doi:10.1016/S0140-6736(07)60784-3
Tett, Cutler, Day, Brown, Bioavailability of hydroxychloroquine tablets in healthy volunteers, Br J Clin Pharmacol, doi:10.1111/j.1365-2125.1989.tb03439.x
Wang, Wang, Ye, Liu, Review of the 2019 novel coronavirus (SARS-CoV-2) based on current evidence, Int J Antimicrob Agents, doi:10.1016/j.ijantimicag.2020.105948
Yao, Ye, Zhang, Cui, Huang et al., In vitro antiviral activity 551 and projection of optimized dosing design of hydroxychloroquine for the 552 treatment of severe acute respiratory syndrome coronavirus 2 553 (SARS-CoV-2), Clin Infect Dis
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop